Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen

Kidney fibrosis is the final common pathway of progressive kidney diseases including diabetic nephropathy. Here, we report that the endogenous antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), the substrate of angiotensin-converting enzyme (ACE), is an orally available peptide dru...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomed Res Int
Päätekijät: Nitta, Kyoko, Shi, Sen, Nagai, Takako, Kanasaki, Megumi, Kitada, Munehiro, Srivastava, Swayam Prakash, Haneda, Masakazu, Kanasaki, Keizo, Koya, Daisuke
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi Publishing Corporation 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818806/
https://ncbi.nlm.nih.gov/pubmed/27088094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/9172157
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia